Home Africa  Laprophan Prices Casablanca IPO at MAD 341 to Fund Polymedic Purchase

 Laprophan Prices Casablanca IPO at MAD 341 to Fund Polymedic Purchase

by Radarr Business Desk

By Radarr Africa Business Desk

CASABLANCA, November 19 (Radarr Africa) – Moroccan pharmaceutical group Laprophan is raising up to MAD 2.22bn in an initial public offering on the Casablanca Stock Exchange, priced at MAD 341 per share, with part of the money earmarked for its purchase of the laboratory Polymedic.

The prospectus was approved by Morocco’s capital markets authority, the AMMC, on October 28, 2026. Subscriptions ran from November 9 to November 17, closing at 3:30 pm on the last day.

Orders are centralised on Thursday, shares are allocated on November 23 and trading begins on November 25, according to the issue timetable. The expected market value is about MAD 5.9bn.

The offer combines a capital increase and a sale of existing shares. It includes 4,105,500 new shares, worth up to MAD 1.4bn, and 2,412,200 existing shares, worth up to MAD 822.56m. Share capital is MAD 132.1m, and the number of shares would rise from 13.2 million to 17.3 million. The offer represents about 37.6 per cent of capital, of which 23.7 per cent is new shares.

The offer is split into three tranches. The first, for orders of at least 8,800 shares, or MAD 3,000,800, takes 72.4 per cent. The second, with no minimum, takes 22.5 per cent, and the third, for employees and executives at a price of MAD 273, takes 5.1 per cent. Non-fund investors are capped at 10 per cent of the shares offered, or 651,770 shares.

Laprophan, founded in Casablanca in 1949, has about 1,450 employees, more than 1,300 marketing authorisations and four production sites in Morocco and Switzerland, and sells its products in 52 countries. Chief executive Farid Bennis called the laboratory a “national asset” given its pioneering history, in the original French “bien national”.

Consolidated revenue rose from MAD 1.503bn in 2023 to MAD 1.82bn in 2025, around 10 per cent a year on average. Operating income in 2025 was MAD 264.6m, up 45.3 per cent, and net income was MAD 109.4m, up 33.9 per cent, equal to 6.0 per cent of revenue compared with 4.0 per cent in 2023. First-half 2026 revenue was MAD 1.354bn, up 11.4 per cent.

In October 2026 the group signed a deal for 100 per cent of Corporate Investment Holding, the parent company of Polymedic, which is subject to approval by the Competition Council. Polymedic, founded in 1964, has about 280 employees, 138 marketing authorisations and more than 200 products. Its 2025 revenue was MAD 405m and it is expected to reach about MAD 455m in 2026.

Laprophan has made other acquisitions. It bought AIF Pharma in March 2024, a 75 per cent stake in Botanic Pharma in September 2024, and a majority stake in the Swiss firm Rivopharm in 2026.

Mediterrania Capital Partners, an investor consortium, entered Laprophan’s capital in 2023. CFG Finance is financial adviser and global coordinator, CFG Marches is lead manager and Attijari Intermediation is co-lead manager.

You may also like

Leave a Comment